MedTrace Logo

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

NCT07353957 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-05-26

No results posted yet for this study

Summary

The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.

Conditions

  • Lung Cancer - Non Small Cell Squamous
  • Lung Cancer - Non Small Cell Non-Squamous

Interventions

COMBINATION_PRODUCT

Petosemtamab + Pembrolizumab

Petosemtamab + Pembrolizumab

Sponsors & Collaborators

  • Merus B.V.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2028-05-31
Completion
2031-02-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Italy
  • Netherlands
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07353957 on ClinicalTrials.gov